UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

22 Apr 2024

UCB receives European Commission approval for BIMZELX[®]▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa

Read More
19 Apr 2024

Acquisition of own shares

Read More
17 Apr 2024

FINTEPLA[®]▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Read More
12 Apr 2024

Acquisition of own shares

Read More
12 Apr 2024

Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY[®]▼ (romosozumab) can help to close the treatment gap in osteoporosis

Read More
12 Apr 2024

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe

© 2007 - 2024 UCB S.A., Belgium. All rights reserved. Last updated on: January, 03, 2024